Combination of EP<sub>4</sub> antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells.

Oncoimmunology · 2021 · PMC7993229 · PMID 33796403

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

showed a trendno p-value reported

As shown in Figure 6a left panel , CT26 tumor weight showed a trend toward reduction in size at day 8 in the MF-766 and MF-766+ muDX400 combination group although the difference did not reach statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.